Join Dr Sofia Ramiro and Professor Xenofon Baraliakos as they discuss the top publications in the world of axSpA. This month, the conversation covered the Association between adalimumab dosing interval and uveitis recurrence in patients with ankylosing spondylitis.
All content for The IMID Forum is the property of The Immune-Mediated Inflammatory Disease Forum and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Join Dr Sofia Ramiro and Professor Xenofon Baraliakos as they discuss the top publications in the world of axSpA. This month, the conversation covered the Association between adalimumab dosing interval and uveitis recurrence in patients with ankylosing spondylitis.
Discussing axSpA: Comparative real-world effectiveness of biologic and targeted therapies in axSpA
The IMID Forum
20 minutes 52 seconds
1 month ago
Discussing axSpA: Comparative real-world effectiveness of biologic and targeted therapies in axSpA
Join Dr Sofia Ramiro and Professor Xenofon Baraliakos as they discuss the top publications in the world of axSpA. This month, the conversation covered the effectiveness of ixekizumab in real-world patients with axSpA and PsA, and the real‑world comparison of clinical effectiveness of UPA, TNF inhibitors or IL‑17 inhibitors in patients with axSpA after switching from an initial TNF inhibitor.
The IMID Forum
Join Dr Sofia Ramiro and Professor Xenofon Baraliakos as they discuss the top publications in the world of axSpA. This month, the conversation covered the Association between adalimumab dosing interval and uveitis recurrence in patients with ankylosing spondylitis.
